immuno-oncology

News

FDA loosens restrictions on first-gen CAR-T therapies

There is enough experience with the first wave of autologous CAR-T therapies to allow strict rules ensuring their safe use to be relaxed, says FDA.

News

BioNTech to buy rival mRNA firm CureVac for $1.25bn

BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.

News

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

Jazz and PharmaMar have revealed the overall survival data with their small-cell lung cancer drug Zepzelca, described as a 'milestone' in the disease.

News

UK trumpets £1bn investment plan from BioNTech

BioNTech has said it will commit up to £1bn in investment in the UK over the next decade, in what has been described as a "template" for the sector.

News

Pfizer snaps up PD-1/VEGF drug from China's 3SBio

Pfizer has joined the ranks of those developing cancer drugs that target PD-1 and VEGF, penning a $6bn licensing deal with China's 3SBio.

News

Incyte's PD-1 drug brings immunotherapy to anal cancer

Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer

FDA loosens restrictions on first-gen CAR-T therapies

BioNTech to buy rival mRNA firm CureVac for $1.25bn

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

UK trumpets £1bn investment plan from BioNTech

Pfizer snaps up PD-1/VEGF drug from China's 3SBio

Incyte's PD-1 drug brings immunotherapy to anal cancer

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

immuno-oncology

Editor's Picks